142 related articles for article (PubMed ID: 24384475)
1. Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?
Azzariti A; Porcelli L; Mangia A; Saponaro C; Quatrale AE; Popescu OS; Strippoli S; Simone G; Paradiso A; Guida M
Exp Cell Res; 2014 Feb; 321(2):240-7. PubMed ID: 24384475
[TBL] [Abstract][Full Text] [Related]
2. Vascular-targeted agents for the treatment of angiosarcoma.
Young RJ; Woll PJ; Staton CA; Reed MW; Brown NJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):259-70. PubMed ID: 24253175
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
4. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Tokuyama W; Mikami T; Masuzawa M; Okayasu I
Hum Pathol; 2010 Mar; 41(3):407-14. PubMed ID: 19913279
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Park MS; Ravi V; Araujo DM
Curr Opin Oncol; 2010 Jul; 22(4):351-5. PubMed ID: 20485168
[TBL] [Abstract][Full Text] [Related]
6. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas.
Itakura E; Yamamoto H; Oda Y; Tsuneyoshi M
J Surg Oncol; 2008 Jan; 97(1):74-81. PubMed ID: 18041747
[TBL] [Abstract][Full Text] [Related]
7. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
9. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
Fanburg-Smith JC; Furlong MA; Childers EL
Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic growth factor expression in benign and malignant vascular tumours.
Young RJ; Fernando M; Hughes D; Brown NJ; Woll PJ
Exp Mol Pathol; 2014 Aug; 97(1):148-53. PubMed ID: 24984271
[TBL] [Abstract][Full Text] [Related]
11. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
13. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
[TBL] [Abstract][Full Text] [Related]
14. Angiosarcoma.
Young RJ; Brown NJ; Reed MW; Hughes D; Woll PJ
Lancet Oncol; 2010 Oct; 11(10):983-91. PubMed ID: 20537949
[TBL] [Abstract][Full Text] [Related]
15. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
16. Angiosarcoma of the breast with delay in diagnosis.
Deutsch M; Werner R
Clin Adv Hematol Oncol; 2004 May; 2(5):320; discussion 321. PubMed ID: 16163199
[No Abstract] [Full Text] [Related]
17. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
18. [Anti-VEGF therapy with bevacizumab in breast cancer].
Tóth J; Gonda A; Szántó J
Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
20. IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.
Taylor KL; Oates RK; Grane R; Leaman DW; Borden EC; Lindner DJ
J Interferon Cytokine Res; 2006 May; 26(5):353-61. PubMed ID: 16689662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
